Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Belgium,Hungary,Czech Republic,Israel,South Africa,Argentina,United States,Portugal,France,Canada
nct
MAJ Il y a 5 ans
Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).
Pays
Argentina
,
Australia
,
Belgium
,
Bosnia and Herzegovina
,
Bulgaria
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Korea, Republic of
,
Malaysia
,
Portugal
,
Romania
,
Serbia
,
Singapore
,
South Africa
,
Spain
,
Taiwan, Province of China
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death
The Primary objective was to assess the efficacy of Celivarone for the prevention of Implantable Cardioverter Defibrillator (ICD) interventions or death. Secondary objectives were: - To assess the tolerability and safety of the different dose regimens of Celivarone in the selected population. - To document Celivarone plasma levels during the study.
Pays
Argentina
,
Australia
,
Belgium
,
Canada
,
Chile
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Japan
,
Mexico
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Turkey
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1